In two decisions published today, the National Institute for Health and Care Excellence (NICE) has approved the drug osimertinib (Tagrisso) to treat some adults in England with advanced lung cancer whose cancer tests positive for a faulty version of a molecule called EGFR.
Around 1,800 people in England have advanced EGFR-positive lung cancer, and the majority are set to benefit from the new recommendations.
First line treatment for advanced lung cancer
Following a rejection last year, and further negotiations between the manufacturer and NHS England on the drug’s price, osimertinib will now be an option for patients whose non small cell lung cancer (NSCLC) has begun to spread to other parts of the body and who have not yet received treatment for their cancer. These cancer cells would also need to test positive for a faulty version of a molecule called EGFR.
Update on my breathing difficulties 
Had to cancel my Lung function tests
So Yet Another Follow Up - Starting I think 2020 - Bizzar,
Clots not clearing up
A sobering experience- and an update to an earlier post
